Chemotherapy, Adjuvant

"Chemotherapy, Adjuvant" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Drug therapy given to augment or stimulate some other form of treatment such as surgery or radiation therapy. Adjuvant chemotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment.

Descriptor ID	D017024
MeSH Number(s)	E02.186.170 E02.319.170
Concept/Terms	Chemotherapy, Adjuvant Chemotherapy, Adjuvant Adjuvant Chemotherapy Drug Therapy, Adjuvant Adjuvant Drug Therapy

Below are MeSH descriptors whose meaning is more general than "Chemotherapy, Adjuvant".

Analytical, Diagnostic and Therapeutic Techniques and Equipment [E]
Therapeutics [E02]
Combined Modality Therapy [E02.186]
Chemotherapy, Adjuvant [E02.186.170]
Drug Therapy [E02.319]
Chemotherapy, Adjuvant [E02.319.170]

Below are MeSH descriptors whose meaning is related to "Chemotherapy, Adjuvant".

Below are MeSH descriptors whose meaning is more specific than "Chemotherapy, Adjuvant".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Chemotherapy, Adjuvant" by people in this website by year, and whether "Chemotherapy, Adjuvant" was a major or minor topic of these publications.

Bar chart showing 33 publications over 16 distinct years, with a maximum of 5 publications in 2017

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1995	0	1	1
2002	0	1	1
2005	0	1	1
2007	0	2	2
2008	0	3	3
2009	0	1	1
2012	0	2	2
2013	0	1	1
2015	0	2	2
2016	0	1	1
2017	1	4	5
2018	1	2	3
2019	0	3	3
2020	0	3	3
2021	1	1	2
2024	0	2	2

Below are the most recent publications written about "Chemotherapy, Adjuvant" by people in Profiles.

Sinicrope FA, Nelson GD, Saberzadeh-Ardestani B, Segovia DI, Graham RP, Wu C, Hagen CE, Shivji S, Savage P, Buchanan DD, Jenkins MA, Phipps AI, Swallow C, LeMarchand L, Gallinger S, Grant RC, Pai RK, Sinicrope SN, Yan D, Shanmugam K, Conner J, Cyr DP, Kirsch R, Banerjee I, Alberts SR, Shi Q, Pai RK. Use of Deep Learning to Evaluate Tumor Microenvironmental Features for Prediction of Colon Cancer Recurrence. Cancer Res Commun. 2024 May 23; 4(5):1344-1350.

View in: PubMed
Corsi NJ, Stephens A, Finati M, Malchow T, Morrison C, Davis M, Hares K, Corsi MP, Arora S, Chiarelli G, Cirulli GO, Autorino R, Sood A, Rogers C, Abdollah F. Testing the external validity of the POUT III trial (adjuvant platnium-based chemotherapy in upper tract urothelial carcinoma) in a North American cohort. Urol Oncol. 2024 Jun; 42(6):175.e19-175.e25.

View in: PubMed
Fukui J, White K, Frankland TB, Oshiro C, Wilkens L. Weight changes according to treatment in a diverse cohort of breast cancer patients. BMC Cancer. 2021 Sep 08; 21(1):1005.

View in: PubMed
Fujii T, Masuda H, Cheng YC, Yang F, Sahin AA, Naoi Y, Matsunaga Y, Raghavendra A, Sinha AK, Fernandez JRE, James A, Yamagishi K, Matsushima T, Schuetz R, Tripathy D, Tada S, Jackson RS, Noguchi S, Nakamura S, Acoba JD, Ueno NT. A 95-gene signature stratifies recurrence risk of invasive disease in ER-positive, HER2-negative, node-negative breast cancer with intermediate 21-gene signature recurrence scores. Breast Cancer Res Treat. 2021 Sep; 189(2):455-461.

View in: PubMed
Chambers LM, Kuznicki M, Yao M, Chichura A, Gruner M, Reizes O, Debernardo R, Rose PG, Michener C, Vargas R. Impact of antibiotic treatment during platinum chemotherapy on survival and recurrence in women with advanced epithelial ovarian cancer. Gynecol Oncol. 2020 12; 159(3):699-705.

View in: PubMed
Amnekar RV, Khan SA, Rashid M, Khade B, Thorat R, Gera P, Shrikhande SV, Smoot DT, Ashktorab H, Gupta S. Histone deacetylase inhibitor pre-treatment enhances the efficacy of DNA-interacting chemotherapeutic drugs in gastric cancer. World J Gastroenterol. 2020 Feb 14; 26(6):598-613.

View in: PubMed
Tran PT, Diaby V. Cost-Effectiveness Analysis of Adjuvant Neratinib Following Trastuzumab in Early-Stage HER2-Positive Breast Cancer. J Manag Care Spec Pharm. 2020 Feb; 26(2):221.

View in: PubMed
Xiao H, Jiang X, Chen C, Wang W, Wang CY, Ali AA, Berthe A, Moussa RK, Diaby V. Using time series analysis to forecast the health-related quality of life of post-menopausal women with non-metastatic ER+ breast cancer: A tutorial and case study. Res Social Adm Pharm. 2020 Aug; 16(8):1095-1099.

View in: PubMed
Shah CH, Balkrishnan R, Diaby V, Xiao H. Examining factors associated with adherence to hormonal therapy in breast cancer patients. Res Social Adm Pharm. 2020 04; 16(4):574-582.

View in: PubMed
Katyan A, Mittal MK, Mani C, Mandal AK. Strain wave elastography in response assessment to neo-adjuvant chemotherapy in patients with locally advanced breast cancer. Br J Radiol. 2019 Jul; 92(1099):20180515.

View in: PubMed

People

Explore

Similar Concepts

Top Journals